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_____________________________________________________________________________________ 
ABSTRACT 
Ligand binding to the extracellular domain of the 
thrombopoietin receptor (TpoR) imparts a specific 
orientation on the receptors' transmembrane (TM) 
and intracellular domains that is required for 
physiologic activation via receptor dimerization. 
To map the inactive and active dimeric 
orientations of the TM helices, we performed 
asparagine (Asn) scanning mutagenesis of the TM 
domains of the murine and human TpoR. 
Substitution of Asn at only one position (S505N) 
activated the human receptor, while Asn 
substitutions at several positions activated the 
murine receptor. Second-site mutational studies 
indicate that His499 near the N-terminus of the 
TM domain is responsible for protecting the 
human receptor from activation by Asn mutations. 
Structural studies reveal that the sequence 
preceding His499 is helical in the murine receptor, 
but non-helical in peptides corresponding to the 
TM domain of the inactive human receptor. The 
activating S505N mutation and the small molecule 
agonist eltrombopag both induce helix in this 
region of the TM domain, and are associated with 
dimerization and activation of the human receptor. 
Thus, His499 regulates the activation of human 
TpoR and provides additional protection against 
activating mutations, such as oncogenic Asn 
mutations in the TM domain. 
________________________________________ 
The thrombopoietin (Tpo)2 or Mpl 
receptor regulates megakaryocyte development 
and supports hematopoietic stem cell survival (1). 
The Tpo receptor (TpoR) shares general homology 
with other members of the cytokine receptor 
family, including the erythropoietin (Epo) and 
granulocyte colony stimulating factor (GCSF) 
receptors (2). These receptors contain a large 
extracellular domain that binds signaling 
hormones in a 2:1 ratio of receptor to hormone (3-
5) along with a single membrane spanning helix 
and an intracellular domain that associates non-
covalently with a tyrosine kinase.  
The minimal functional region of the 
intracellular domain stretches from the boundary 
of transmembrane (TM) domain and includes three 
regions with limited sequence homology: a 
conserved switch region, Box 1 and Box 2. The 
switch region contains a hydrophobic motif whose 
orientation is required for signaling (6,7). Box 1 is 
characterized by a proline rich motif (PXXPXP) 
that is crucial for cytokine receptors to bind and 
activate their cognate Janus kinases (JAKs) (8-10). 
Box 2 is loosely defined as a motif with acidic and 
hydrophobic residues and is required for maximal 
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cell growth in response to cytokines.  
The TpoR has several unique features. 
First, the extracellular domain is duplicated, and 
deletion of the membrane distal domain causes 
constitutive activation (11). Second, there are 5 
amino acids (RWQFP) inserted directly C-
terminal to the TM domain whose deletion or 
mutation causes ligand-independent receptor 
activation (12). Finally, clinically relevant 
mutations have been identified that induce 
constitutive receptor activity in the extracellular 
juxtamembrane (JM) region (T487A, (13)), the 
TM domain (S505N, (14,15)) and in the 
intracellular RWQFP motif (W515K/L/A, (12,16-
19)). The fact that these are clustered in and 
around the TM domain reflects the importance of 
this region in the regulation of receptor activation.  
It is generally accepted that the active 
signaling form of cytokine receptors is a dimer, 
but whether the inactive state is dimeric or 
monomeric is unknown. Several lines of evidence 
exist to suggest that the Epo receptor (EpoR), one 
of the most extensively studied cytokine receptors, 
exists as a preformed dimer and activation is 
induced by structural reorganization of the dimer 
after hormone binding. Crystallographic studies of 
the EpoR extracellular domain in the presence and 
absence of ligand suggest that the full-length 
inactive receptor is dimeric and hormone binding 
causes subunit rotation for activation (4,20). A 
similar model has been proposed for the 
structurally related growth hormone receptor (21-
23). The first evidence that the TM domain 
contributes to dimerization of the inactive EpoR 
came from co-patching measurements using 
chimaeras of the prolactin and Epo receptors in 
HEK293-derived BOSC cells (24). These studies 
found the TM domain of the EpoR to be both 
necessary and sufficient for receptor dimerization 
in the context of the full-length receptor. This 
conclusion is supported by biophysical 
measurements showing that the isolated TM 
domain of the murine EpoR associates as a dimer 
(25). However, unlike the TpoR, the TM domain 
of the EpoR is not a hot-spot for activating 
mutations.  
Much less is known about whether the 
TpoR forms an inactive dimer that changes 
orientation upon ligand binding. Studies using 
coiled-coil fusions to the TM-cytosolic domain of 
the murine TpoR showed that one dimeric 
interface is inactive, one interface mimics the 
physiologic functions of TpoR and several 
orientations induce partial levels of activation in 
vitro and in bone marrow transplantation 
experiments in vivo in mice (26). However, these 
studies use an artificial receptor where the large, 
native extracellular domain dimer (preformed or 
ligand-bound) is replaced with a short, tightly 
associated coiled coil that forces symmetric 
dimerization. Biophysical studies on the 
association of the human TpoR TM domain using 
cysteine mutagenesis and the TOXCAT reporter 
assay indicate that the wild type TM sequence 
(residues 491-515) associates as a dimer (27). 
However, we have recently shown that the five 
amino acid (RWQFP) insert at the intracellular 
TM-JM boundary of the TpoR impairs 
dimerization of the upstream TpoR TM helix (28). 
We further showed that mutation of Trp515 within 
this motif leads to dimerization of the TM-JM 
region of TpoR by changing the orientation of the 
TM helix relative to the membrane bilayer normal 
(28). While the studies on isolated TM-JM regions 
of TpoR reveal that they have a propensity to 
dimerize, it remains an open question as to 
whether the full-length receptor is primarily 
dimeric, monomeric or exists in a monomer-dimer 
equilibrium.  
In this study, asparagine-scanning 
mutagenesis of the murine TpoR (mTpoR) and 
human TpoR (hTpoR) was used to modulate the 
orientation and dimerization of the TM domain of 
the receptor. The asparagine mutations provide an 
alternative to the coiled-coil dimerization 
sequences we have previously used to engineer 
TpoR dimers (26). Asparagine is able to mediate 
dimerization of TM helices through strong 
hydrogen bonding interactions, and often does so 
in a sequence-independent fashion (29-31). 
Moreover, asparagine-scanning mutagenesis 
addresses the question of whether the clinically 
observed S505N mutation in humans is unique or 
just one of many mutations that lead to 
constitutive activation. We make use of full-length 
receptors, truncated receptors, and peptides 
corresponding to only the TM-JM domain for 
comparative studies between the murine and 
human receptors. Together, our results provide the 
structural basis for why the hTpoR cannot be 
activated by asparagine mutations that readily 
activate the mTpoR, suggesting an evolutionary 
mechanism that results in resistance to oncogenic 
activation of hTpoR.  
 
EXPERIMENTAL PROCEDURES 
cDNA Constructs and Cells—Mouse and 
human TpoR cDNAs cloned in the pMX-IRES-
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GFP bicistronic vector contained a hemagglutinin 
(HA) tag at the NH2-terminus. Site-directed 
mutagenesis was achieved by the overlapping-
extension PCR amplification method. The PCR 
reaction was performed using 1 µl of pfuTurbo 
DNA polymerase (2.5 U/µl) following the 
protocol in the QuickChange XL site-directed 
mutagenesis kit (Stratagene, Santa Clara, CA), as 
described (28). Sanger sequencing of the entire 
coding region was used for each construct. 
Cell Proliferation Assay—Pro-B 
interleukin 3 (IL-3) dependent Ba/F3 cells were 
maintained in RPMI 1640 and 10% fetal calf 
serum using WEHI cell supernatant as a source of 
IL-3. TpoR Asn variants subcloned in the pMX-
IRES-GFP were used for packaging ectopic 
retrovirus in BOSC cells. Cells were infected in 
medium containing polybrene with packaged 
retrovirus and cell pools expressing similar levels 
(top 15%) of green fluorescence protein (GFP) 
coded by the bicistronic retroviral vectors were 
isolated using flow cytometry cell sorting. Cell-
surface TpoR was assessed by staining with anti-
HA antibodies (Covance, Princeton, NJ; 10 
 µg/ml) and phycoerythrin conjugated donkey 
anti-mouse IgG secondary antibodies (28). The 
levels of TpoR total protein expression were 
determined by Western blotting using anti-HA 
antobodies (Roche Pharmaceuticals). For 
determining the maturation state of the N-
glycosylated TpoR mutants we used digestion with 
Endoglycosidase H (Endo-H) for 4 h followed by 
Western blotting with anti-HA antibodies, as 
described (6). Cell proliferation in the presence or 
absence of cytokines was measured using the 
CellTiter-Glo Luminescent cell viability assay 
(Promega, Madison, WI). 
Dual-luciferase Transcriptional Assay of 
STAT Activation—Transcriptional activation of 
STAT3 and STAT5 downstream TpoR variants 
was assessed in γ-2A cells (JAK2-deficient cells 
reconstituted with JAK2) using the dual-luciferase 
assay kit (Promega, Madison, WI). The assay 
measures luciferase luminescence after transient 
transfection of the pGRR5 reporter containing the 
firefly luciferase and STAT3/STAT5 binding sites 
and a control reporter (pRL-TK) containing 
Renilla luciferase. The ratio luminescence of these 
two luciferases provides a measure of STAT 
activation (26,32). Luminescence was detected in 
cell lysates with a Perkin-Elmer Victor-X light 
analyzer. 
Split-Luciferase Complementation Assay 
of Receptor Dimerization—TpoR dimerization was 
measured using a complementation assay in which 
two halves of Gaussia princeps luciferase were 
attached separately to the C-terminus of TpoR. 
The cDNA of TpoR was inserted between the Notl 
and Clal restriction sites of the pcDNA3.1/Zeo 
vector upstream of either the hGluc fragment 
coding amino acids 1–93 (hGluc1) or the fragment 
coding amino acids 94–169 (hGluc2) of Gaussia 
princeps luciferase (33). BOSC cells plated on 24-
well plates were co-transfected with the plasmids 
(coding hGluc1and hGluc2) using Lipofectamine 
(Invitrogen). Twenty-four hours after transfection 
cells were trypsinized and resuspended in 150 µL 
of DMEM/F-12 without phenol red (Gibco). Cell 
samples were flash-frozen on dry ice for 10 min 
and thawed in a water bath at 37 °C for 10 min 
(cycle was repeated twice). After centrifugation 
(10,000 g, 5 min) the supernatants were collected 
and aliquoted (100 µL per well) in 96-well white 
plates (Nunc, Thermo Fisher Scientific) to 
measure the luciferase activity. Native 
coelenterazine (NanoLight Technology) was 
reconstituted as a stock solution (1 mg/mL in 
methanol) and diluted to a final concentration of 
20 µM in DMEM/F12 at room temperature for 
injection (100 µL). Signal intensities (integrated 
over 10 s, with an injection delay of 2 s) were read 
on a Perkin-Elmer Victor X light analyzer. 
Aliquots of the supernatants were also used to 
detect the proteins on Western blots (33).  
Membrane Reconstitution of TM-JM 
peptides for Biophysical Studies—Peptides (40 
residues in length) corresponding to the TM 
domain and JM regions of hTpoR 
(TRVETATETAWISLVTALHLVLGLSAVLGL
LLLRWQFPAH) and mTpoR 
(ARVSTGSETAWITLVTALLLVLSLSALLGLL
LLKWQFPAH) were synthesized using solid-
phase methods. Deuterated (5,5,5-D3) leucine and 
deuterium-free water were purchased from 
Cambridge Isotope Laboratories (Andover, MA). 
Other amino acids and octyl-ß-glucoside were 
obtained from Sigma Chemical (St. Louis, MO). 
The crude peptide (5–15 mg) was purified by 
reverse-phase HPLC on a C4 column using 
gradient elution. Purified TpoR peptides were 
reconstituted by detergent dialysis using DMPC 
and DMPG (10:3) and a ~1:60 peptide-to-lipid 
ratio. Lipids were obtained from Avanti Polar 
Lipids (Alabaster, AL) as lyophilized powders and 
used without further purification. The lipid, 
detergent and peptide were dissolved in organic 
solvent (e.g. hexafluoro-2-propanol or 
trifluoroethanol). The mixture of lipid, detergent 
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and peptide in organic solvent was incubated at 37 
°C for over 2 h, and the solvent was removed by 
evaporation using a stream of argon gas and then 
the sample was placed under vacuum. The dry 
mixture was rehydrated with phosphate buffer (10 
mM phosphate and 50 mM NaCl, pH 7.4) such 
that the final concentration of octyl-ß-glucoside 
was 5-10% (w/v). The rehydrated sample was then 
stirred slowly for at least 6 h, and the octyl-ß-
glucoside was removed by dialysis using Spectra-
Por dialysis tubing (3500 MW cutoff) for 24 h 
against phosphate buffer at 37 °C. To confirm that 
the membrane-reconstituted peptides did not 
aggregate during dialysis, the samples were loaded 
onto 10-40% (w/v) sucrose gradients and purified. 
Samples for IR spectroscopy were dialyzed a 
second time to remove sucrose. The dichroic ratios 
were compared before and after dialysis. Samples 
for NMR spectroscopy were pelleted by 
ultracentrifugation and, if needed, washed twice to 
remove sucrose. The pelleted samples were 
lyophilized, rehydrated with deuterium-depleted 
water (50 ± 5% weight) and incubated at 37 °C for 
24 h before loading into NMR rotors.  
Polarized IR Spectroscopy—Polarized 
attenuated total reflection (ATR) Fourier 
transform infrared (FTIR) spectra were obtained 
on a Bruker IFS 66V/S spectrometer. 
Reconstituted hTpoR and mTpoR TM-JM 
peptides (50-100 µg) were layered onto a 
germanium internal reflection element using a 
slow flow of air or argon gas directed at an oblique 
angle to the ATR plate to form an oriented 
multilamellar lipid-peptide film. IR spectra were 
obtained using light having either parallel or 
perpendicular polarization relative to the surface 
of the germanium plate. The dichroic ratio (RATR) 
is defined as the ratio between the absorption of 
parallel (All) and perpendicular (A⊥) polarized 
light. The frequency of the amide I vibration is 
sensitive to the global secondary structure of 
protein and the dichroic ratio of the amide I band 
provides information on the orientation of TM 
helices relative to the plane of the membrane (34). 
A detailed analysis has been described previously 
(34). 1000 scans were acquired and averaged for 
each sample at a resolution of 4 cm-1. The 
calculation of the helix tilt angles from the 
observed dichroic ratios was based on a value of 
the transition moment angle (α) of 39.5° and a 
maximum membrane order parameter (Smem) of 
0.85 (34). The use of the values of α and Smem are 
based on measurements of bacteriorhodopsin, an 
integral membrane protein with 7 transmembrane 
helices of known structure and which forms well-
ordered, two-dimensional membrane arrays. We 
do not independently know the disorder of the 
reconstituted TM helices in our samples. 
Consequently, we assume that the maximum order 
obtained is equal to that of bacteriorhodopsin 
obtained from diffraction measurements (35). This 
results in a lower estimate for the helix tilt angles 
reported in Table 1 (i.e. greater disorder in our 
membrane reconstitutions than that found for 
bacteriorhodopsin would correspond to lower 
actual tilt angles for an ideal sample with no 
disorder).  
Solid-state NMR Spectroscopy—
Deuterium NMR spectra were obtained at a 2H 
frequency of 55.2 MHz on a Bruker Avance NMR 
spectrometer using a 4 mm MAS probe. A MAS 
frequency of 3 kHz was used to increase the 
number of spinning side bands. Single pulse 
excitation was employed using a 4 - 7.5 µsec 90° 
pulse, followed by a 4.5 µsec delay before data 
acquisition. The repetition delay was 0.25 sec. A 
total of 600,000 - 1,500,000 transients were 
averaged for each spectrum and processed using a 
100 Hz exponential line broadening function. 
Spectra were obtained at 25 °C.  
2D dipolar assisted rotational resonance 
(DARR) NMR experiments (36) were performed 
at a 13C frequency of 125 MHz on a Bruker 
AVANCE spectrometer. The MAS spinning rate 
was set in the range of 9-11 KHz (± 5 Hz). The 
ramped amplitude cross polarization contact time 
was 2 ms. Two-pulse phase-modulated decoupling 
was used during the evolution and acquisition 
periods with a radiofrequency field strength of 80 
kHz. Internuclear 13C…13C distance constraints 
were obtained from using a mixing time of 600 
ms. The sample temperature was maintained at -50 
°C (± 2 °C). All 13C solid-state MAS NMR spectra 
were externally referenced to the 13C resonance of 
neat TMS at 0 ppm at room temperature. Using 
TMS as the external reference, we calibrated the 
carbonyl resonance of solid glycine at 176.46 
ppm. The chemical shift difference between 13C of 
DSS in D2O relative to neat TMS is 2.01 ppm. 
 
RESULTS 
Asparagine Mutations in the 
Transmembrane Domain of the Human and 
Murine TpoR Induce Different Effects—The TM 
sequences of human and murine receptors are 
shown in Fig. 1A along with a consensus sequence 
for mammalian TpoRs. Across a wide range of 
species, the TM domain is relatively well 
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conserved. Ser505 and Trp515 both have a 
sequence identity of ~96%. The S505N is 
associated with familial forms of thrombocytosis, 
while the W515K,L,A mutations are associated 
with essential thrombocythemia and primary 
myelofibrosis. There are only a few residues with 
less than 90% identity (shown in red). There are 
four differences between human and mouse in the 
TM-JM sequence shown. Based on sequence 
comparison between TpoRs from 50 species, 
leucine at positions 492 and 500 in the mouse, and 
glycine and arginine at positions 503 and 514, 
respectively, in the human are the consensus 
residues.  
Asparagine, the residue that leads to 
constitutive activation upon mutation at Ser505 
(human), is able to mediate dimerization of TM 
helices as left-handed coiled coils. The early 
studies of leucine zippers involved Asn residues at 
the “a” position in the heptad repeat characteristic 
of a left-handed coiled coil (37,38). The crystal 
structure of the GCN4 transcription factor shows 
that the amide side chain of Asn forms an 
asymmetric hydrogen bond across the dimer 
interface (38) and dimerization studies showed 
that this contributes about -2 kcal/mol of binding 
energy (39).  
Helical wheel diagrams illustrate the 
possible dimer interfaces in hTpoR and mTpoR 
(Fig. 1A,B). Such dimeric interfaces are imposed 
when the coiled-coil domain of Put3 is fused at 
consecutive positions to the TM domain of 
mTpoR, thus replacing the extracellular domain 
(26). There are seven possible symmetric 
interfaces that might mediate dimerization in the 
native receptor and that were created by 
progressive deletion of residues from the N-
terminal end of the TM domain after fusion with 
the Put3 coiled coil (26). These are designated cc-
TpoR-0 through cc-TpoR-VI. The cc-TpoR-II 
interface was found to be inactive, whereas the 
other interfaces exhibited various degrees of 
activity.  
To investigate whether the full-length 
TpoR can be activated by asparagine mutations on 
different TM helix interfaces, TM residues 503-
510 were individually substituted with asparagine 
in the hTpoR and the receptor activity was 
monitored using a luciferase assay that reports on 
STAT5 transcriptional activation (see Methods). 
Substitution with Asn only at a single position 
(S505N) leads to ligand independent activation of 
the hTpoR (Fig. 1C). This position is the same as 
that detected in clinical studies showing only a 
single site (Ser505) where an Asn mutation leads 
to disease. The results on STAT5 transcriptional 
activity were confirmed with cell proliferation 
assays in stable Ba/F3 transduced cells (Fig. 1D). 
For these measurements, each receptor mutant was 
retrovirally transduced into Ba/F3 cells and sorted 
using flow cytometry for similar levels of 
expression. Only the S505N mutant led to 
cytokine independent cell proliferation. 
Importantly, several substitutions (L508N, 
G509N, L510N) led to receptors that were unable 
to traffic to the cell surface and were, as a 
consequence, inactive when Tpo was added. 
Asparagine scanning measurements of 
STAT5 transcriptional activation of the mTpoR 
reveal a very different picture (Fig. 2A). In 
contrast to hTpoR, asparagine substitutions at 
positions 494, 498, 500, 501 and 502 in mTpoR 
stabilize active receptors in the absence of ligand. 
These results were confirmed by cell proliferation 
assays in Ba/F3 cells for positions 494, 498, 500 
and 502 (Fig. 2B). Asn substitutions at 4 different 
positions of the mTpoR clearly lead to activation, 
while only S505N (equivalent to S498N in the 
mouse) activates the hTpoR. 
Mutation of His499 to leucine leads to 
increased cell-surface localization and signaling 
by the hTpoR G509N mutant- One of the largest 
sequence differences in the TM and JM regions 
between the murine and human receptors is at 
position 499 where histidine in human (His499) is 
replaced by leucine in mouse (Leu492). This TM 
residue is unique to TpoR and GCSFR within the 
family of type-I cytokine receptors and only 
appeared later in species evolution. The histidine 
in the human receptor has previously been shown 
to bind eltrombopag, a small molecule agonist of 
hTpoR, leading to receptor activation (40). In this 
section, we explore the influence on activation of 
the H499L and L492H mutants in the context of 
the human and murine receptors, respectively, and 
show how these mutations influence the ability of 
Asn substitutions within the TM domain to 
activate TpoR. STAT5 activation and cell 
proliferation were measured using the dual-
luciferase and the cell viability assays, 
respectively, on the murine (A) and human (B) 
receptors with swapped residues (i.e. H499L and 
L492H) (Fig. 3). Several conclusions can be 
drawn.  
First, mTpoR G502N (the most strongly 
activating single Asn mutant) is not active in the 
context of the mTpoR G502N/L492H double 
mutant. Indeed, placement of histidine at position 
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492 in the mTpoR G502N mutant abolished the 
activity of the mutant in the absence and the 
presence of ligand, yielding the same phenotype as 
the human receptor with the corresponding G509N 
substitution.  
Second, the mTpoR is not sensitive to 
eltrombopag, while substitution of L492H in the 
mTpoR imparts sensitivity to eltrombopag as 
previously observed (40). This confirms that 
eltrombopag binding requires the presence of 
histidine in the TM sequence. In contrast, removal 
of histidine at position 499 in the hTpoR-G509N 
mutant could restore the activity of this mutant in 
the presence and in the absence of ligand. As a 
control, the human receptor lacking His499 could 
no longer respond to eltrombopag. 
Third, the hTpoR-G509N mutant 
(equivalent to mTpoR G502N) does not traffic to 
the plasma membrane. The hTpoR-G509N mutant 
is retained intracellularly in an endoglycosidase H 
(EndoH)-sensitive form (Fig. 4), indicating it 
contains high mannose N-glycosylation, 
characteristic of immature receptor retained in the 
endoplasmic reticulum (ER), or possibly a 
receptor that cannot progress past the cis-Golgi. In 
contrast, the double mutation (H499L, G509N) 
allows the receptor to traffic to the plasma 
membrane (Fig. 4), and to induce STAT5 
activation and autonomous proliferation in Ba/F3 
cells (Fig. 3C). H499L appears to also rescue 
activity for additional Asn mutants in the hTpoR. 
For example, V507N is partially rescued by the 
H499L mutation and exhibits weak activity (data 
not shown). Rescued receptors become EndoH-
resistant and are localized at the cell-surface (Fig. 
4). In the background of the mouse TpoR, the 
L492H mutation inactivates the Asn mutants and 
impairs their ability to traffic to the cell-surface 
(data not shown).  
Dimerization of hTpoR Causes 
Straightening of the TM Helix near His499—The 
structural basis underlying the mechanism by 
which His499 influences receptor activation and 
cell surface expression is a challenge to study in 
full-length Tpo receptors. However, the original 
studies describing the influence of Asn mutations 
on TM helix dimerization were undertaken on 
isolated TM domains that independently fold into 
helical secondary structure when reconstituted into 
membrane bilayers (29-31). Indeed, we have 
previously shown that the activating S505N and 
W515K mutations in the context of TM-JM 
peptides of the human TpoR lead to a change of 
the tilt angle of the TM helix and induce 
dimerization, consistent with measurements on the 
full-length receptor using the split-luciferase assay 
(28). Here, we extend these studies to the G509N 
and H499L mutants in hTpoR and to the G502N 
and L492H mutants in mTpoR (Table 1).  
Polarized FTIR spectroscopy provides 
information on the global secondary structure and 
orientation of membrane-reconstituted TM-JM 
peptides. Typically these peptides fold into α-
helical secondary structure that gives rise to an 
amide I vibrational band at ~1655 cm-1 in the IR 
spectrum. The orientation of the TM helix (i.e. the 
helix tilt angle relative to the bilayer normal, see 
Methods) is probed in polarized IR spectra by 
measurements of the dichroic ratio (RATR). 
Hydrophobic peptides (20-24 residues in length) 
typically exhibit dichroic ratios of >3.0, 
corresponding to a maximum helix tilt of ~28°. 
Lower dichroic ratios indicate something unusual 
in the TM sequence (or simply reflect poor 
membrane reconstitutions). Our previous FTIR 
studies on hTpoR TM-JM peptides revealed 
dichroic ratios of ≤ 2.8 (28). In Fig. 5A,B we show 
using parallel reconstitutions that mTpoR-WT 
peptides exhibit a striking increase in the dichroic 
ratio compared to hTpoR-WT, corresponding to a 
decrease in the helix tilt angle from 35° to 20°. 
This change in orientation can be mimicked in the 
hTpoR by the H499L mutation, which exhibits the 
same dichroic ratio (3.2) within error as the 
mTpoR (Table 1).  
A second mechanism for increasing the 
dichroic ratio of the hTpoR-WT TM helix is 
incorporation of the S505N mutation. The hTpoR-
S505N dichroic ratio (3.4) is closer to mTpoR-WT 
(3.3) than to hTpoR-WT (2.7). We attribute this 
increase to a shift in the monomer-dimer 
equilibrium toward dimer in the S505N mutant 
(28). The mTpoR-S498N and hTpoR-S505N 
peptides exhibit similar dichroic ratios (3.3 versus 
3.4), suggesting they adopt similar active 
orientations. 
We also compared the homologous 
hTpoR-G509N and mTpoR-G502N mutants. The 
mTpoR-G502N peptide has a much higher 
dichroic ratio (3.2) than hTpoR-G509N (2.5) 
consistent with the higher activity of the full 
length mTpoR-G502N mutant. The dichroic ratio 
of hTpoR-G509N is slightly lower than hTpoR-
WT (2.7). The presence of two polar residues 
(His499 and Asn509) appears to alter the 
orientation of the TM helix in the membrane and 
may be associated with the poor ability of the 
G509N mutant to traffic. Similarly, introducing a 
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histidine (at the equivalent His499 position) in the 
murine coiled-coil constructs induces TpoR 
protein instability as observed by loss of activity 
and protein expression at the cell surface (data not 
shown).  
Previous NMR studies on the structure 
and orientation of the TM helix of hTpoR found 
that there was a break in helical secondary 
structure near Ala497, one turn before His499 
(41). The low dichroic ratio of the amide I band 
observed in FTIR spectra of wild-type hTpoR 
would be consistent with this observation. To 
directly probe the helical secondary structure in 
this region of the peptide in mTpoR and hTpoR, 
we made use of intramolecular distance 
measurements using two-dimensional (2D) 13C 
NMR spectroscopy with magic angle spinning 
(MAS) (36).  
2D 13C NMR spectra were obtained on the 
hTpoR and mTpoR TM sequences isotopically 
labeled with 1-13C-Leu494/487, 1-13C-Val495/488, 
and 13Cβ-Ala497/490 (human/mouse TpoR 
numbering). These positions just precede His499 
or Leu492 in the hTpoR and mTpoR sequences, 
respectively. In the 2D NMR spectra, 
intramolecular cross peaks are observed between 
13C sites with a through-space separation of ≤ 6 Å. 
For example, in mTpoR the 13Cβ-carbon of 
Ala490 is in close proximity to the 13C=O groups 
of Leu487 (4.3 Å) and Val488 (5.4 Å) in α-helical 
secondary structure, and cross peaks between 
these 13C-resonances are observed in the 2D NMR 
spectrum. Fig. 5C shows the full 2D DARR 
spectrum of mTpoR-WT where a distinct cross 
peak is observed between 13Cβ Ala490 and either 
13C=O Leu487 and/or Val488, whose resonances 
are not resolved. The cross peak (highlighted in 
Fig. 5E) confirms this region of mTpoR-WT is α-
helical. In contrast, this cross peak is absent in 
hTpoR (Fig. 5D) revealing that this region does 
not adopt helical secondary structure. 
In addition to the observation of intra-
helical cross peaks in mTpoR, there are distinct 
changes in chemical shifts of the 13C=O 
resonances between the hTpoR and mTpoR 
sequences (Table 1). The 13C=O chemical shifts 
above ~174 ppm in the mTpoR-WT peptide are 
consistent with a helical geometry, whereas 
chemical shifts below ~174 ppm are consistent 
with unraveling of the helix just N-terminal to 
His499.  
Table 1 summarizes the polarized IR and 
NMR measurements on hTpoR-WT, mTpoR-WT 
and several mutants. There is a general correlation 
between the dichroic ratio and the presence of 
helical secondary structure above the Leu492 
(mTpoR) and His499 (hTpoR). That is, the TM 
helices adopt a more parallel orientation (low tilt) 
when helical structure is observed around Leu492 
or His499. In the section below, we show that 
these changes are associated with the ability of the 
TM helix to dimerize. The comparisons suggest 
that hTpoR-H499L is structurally similar to 
mTpoR-WT, and mTpoR-L492H is structurally 
similar to hTpoR-WT.  
The TM Domain of mTpoR has a Stronger 
Propensity to Dimerize than hTpoR—In the wild-
type and mutant TpoR peptides, dimerization can 
be estimated from deuterium MAS NMR spectra 
(28). In these experiments, the peptides are 
deuterated at Leu512 (hTpoR) or Leu505 
(mTpoR). Comparison of the deuterium MAS 
NMR spectra of hTpoR-WT and mTpoR-WT 
reveals a large difference in the MAS spectra (Fig. 
6A,B). We have previously shown that fast 
rotational diffusion of the hTpoR monomer results 
in the loss of the side band pattern and that 
mutations in the TM and JM regions that lead to 
dimerization restore the MAS rotational side bands 
(28). On the basis of the observed sideband 
pattern, we conclude that the monomer-dimer 
equilibrium in mTpoR-WT is shifted toward dimer 
compared to hTpoR-WT. The deuterium side band 
pattern characteristic of dimerization is observed 
for the activating mutants of hTpoR (S505N, 
G509N) (Table 1). TM dimerization is also 
observed for the activating mutants of mTpoR 
(S498N, G502N and W508K).  
The Gaussia princeps luciferase 
complementation assay (28,33) was used to assess 
the dimerization status of the full length, as well as 
of truncated mouse and human TpoRs containing 
transmembrane/intracellular (TM-IC) domains,. In 
this assay, two proteins of interest are fused to 
complementary fragments of Gaussia princeps 
luciferase, denoted hGluc1 and hGluc2. If the 
proteins interact, luciferase fragments are brought 
together, fold into their native structure and the 
reconstituted luciferase enzyme catalyzes the 
oxidation of the substrate coelenterazine, which 
can be detected and quantified using luminescence 
readers.  
The carboxyl terminus of murine or 
human TpoR was fused to complementary 
fragments of Gaussia princeps luciferase (hGluc1 
and hGluc2) and transiently co-expressed in 
BOSC cells where their expression levels were 
comparable and could be assessed by Western blot 
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(data not shown). The expression of these 
constructs individually, as expected did not result 
in reconstitution of luciferase activity (28). The 
complementation of hGluc-tagged murine and 
human full-length TpoR was relatively low and 
appeared to be at similar levels (Fig. 6C, condition 
1 and 2), indicating that the level of preformed 
dimers detected by proximity of cytosolic domains 
is low. Importantly, removal of the extracellular 
domain resulted in significantly higher 
dimerization of the mTpoR (condition 4), but not 
of the hTpoR (condition 3) whose dimerization 
remained the same compared to the full-length 
receptor. Thus, the hTpoR TM-IC segment 
possesses an additional mechanism to prevent its 
self-dimerization that could be ascribed to His499. 
Indeed, substitution of His499 to leucine allows 
dimerization of the TM-IC form of hTpoR 
(condition 5), while substitution of Leu492 to 
histidine in the TM-IC form of the mTpoR 
dramatically decreased dimerization, as assayed by 
luciferase complementation (condition 6).  
The results in Fig. 6C for the TM-IC 
constructs are consistent with the NMR analysis of 
the TM-JM peptides, namely that His499 prevents 
dimerization of the TM domain of hTpoR in the 
context of a truncated TpoR lacking the 
extracellular domain. Using the dual-luciferase 
assay to monitor receptor activity, we show in Fig. 
6D that the TM-IC constructs of mTpoR are 
inactive despite increased dimerization. In the 
hTpoR constructs, truncation of the extracellular 
domain abolishes Tpo-dependent activity, yet still 
allows activation upon the addition of 
eltrombopag. This activation is not detected in the 
H499L mutant.  
Eltrombopag Induces Dimerization of 
hTpoR TM Helix Peptides—Comparison of the 
hTpoR and mTpoR TM-JM peptides shows that 
the monomer-dimer equilibrium is shifted toward 
monomer in hTpoR-WT compared to mTpoR-WT 
(Fig. 6A,B). Binding of the small molecule agonist 
eltrombopag induces receptor activation and 
requires the presence of His499 (40). In the 
absence of activation, His499 was previously 
shown to cause a kink in the TM helix (41). We 
asked whether this structure changes in the 
presence of eltrombopag, and whether 
eltrombopag influences dimerization of the hTpoR 
TM domains. Comparison of hTpoR WT peptides 
without (Fig. 6A) and with eltrombopag (Fig. 7B) 
shows a slight increase in the intensity of the 
deuterium MAS side bands, consistent with a shift 
toward the peptide dimer. Furthermore, the 
secondary structure around His499 becomes 
helical in the hTpoR-WT peptide in the presence 
of eltrombopag (Table 1). Increased dimerization 
agrees with the studies on the TM-IC constructs 
containing the full IC domain, which exhibit an 
increase in activity upon eltrombopag binding 
(Fig. 6D). We also asked whether substituting 
His499 with leucine, the corresponding residue in 
mTpoR would influence dimerization. Indeed, 
hTpoR H499L also becomes more dimeric 
compared to hTpoR-WT (Fig. 7C), consistent with 
an observed increase in the dichroic ratio from 
polarized IR measurements (Table 1), while the 
mTpoR L492H peptide becomes more monomeric 
compared to mTpoR-WT (Fig. 7A). The dimeric 
interfaces in Fig. 7B and C are predicted to be 
different, between the inactive dimeric and active 
dimeric states of hTpoR (see below).  
Rotational Orientation of TM Helices in 
Inactive and Active Dimers—Interhelical NMR 
measurements of specifically labeled 41 residue 
mTpoR peptides (Glu481 to Ser524) allow us to 
probe the interface that mediates dimerization. In 
these experiments, two mTpoR peptides with 
complementary 13C labeling were reconstituted 
together into DMPC:DMPG bilayers at a peptide: 
lipid molar ratio of 1:60. The positions of the 
labels were selected on the basis of our previous 
engineered Put3 constructs that defined the 
inactive and active interfaces. 
To probe the inactive dimer interface, 2D 
13C NMR spectra were obtained on mTpoR-WT 
peptides containing 13C-labeled Ala499 and 
Gly502. One peptide was labeled with 13Cβ-
Ala499 and 13C=O Gly502, and the other was 
labeled with 13C=O Ala499 and 13Cα Gly502. 
Ala499 is predicted to be in the inactive interface, 
while Gly502 is at the boundary between inactive 
and active interfaces. We observe a cross peak 
between the diagonal 13Cβ and 13C=O resonances 
of Ala499 (Fig. 8A) and between the diagonal 
13Cα and 13C=O resonances of Gly502 (Fig. 8B). 
These 13C-labeled carbons are on different 
peptides, and the cross peak intensities are 
consistent with an interhelical Ala499 Cβ to C=O 
distance of ~5.4 Å, and an interhelical Gly502 Cα 
to C=O distance of ~5.2 Å. An intrahelical cross 
peak is also observed between the Gly502 13Cα 
resonance and the Ala499 13C=O resonance. These 
13C labels are on the same peptide, and are 
estimated to be ~4.4 Å apart in an α-helical 
geometry. An intrahelical cross peak between the 
Ala49913Cβ and Gly502 13C=O resonances was 
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not observed as the distance between 13C sites is 
>6 Å in an α-helix.  
To probe the potential active interface(s), 
parallel 2D NMR experiments were undertaken on 
mTpoR-S498N (Fig. 8C,D). In contrast to the 
results above, we do not observe interhelical 
Ala499-Ala499 or Gly502-Gly502 cross peaks in 
peptides containing this activating mutation 
confirming that we lose the inactive interface. The 
absence of contacts between these residues is 
consistent with a shift in the dimer interface to 
either the active cc-TpoR-I or cc-TpoR-V 
interfaces defined by engineered Put3 dimers, both 
of which contain Ser498 in the interface. 
Models of the TM domain of the hTpoR in 
inactive and active orientations are shown in Fig. 
9A. The inactive receptor exists in a monomer-
dimer equilibrium. The split luciferase 
measurements of the full-length receptor along 
with deuterium NMR measurements of the 
hTpoR-WT TM-JM peptides indicate that the 
equilibrium is shifted toward monomer. His499 
induces a break in the TM helix. The side chain of 
His499 is predicted to reside within the headgroup 
region of phospholipids on the extracellular side of 
the bilayer. Given the bilayer thickness, this 
requires the RWQFP motif to partition into 
headgroup region of the phospholipids on the 
intracellular side of the bilayer. The active 
orientation is modeled as a dimer (Fig. 9A, right). 
In the wild-type full-length receptor, ligand 
binding drives a shift of the receptor dimer to an 
active orientation with Ser505 in the interface. 
Dimerization is also mediated by hydrogen 
bonding interactions involving the Asn side chains 
in the S505N mutant (Fig. 9A, right). In the TM-
JM peptides, dimerization induces helical 
secondary structure in the region just N-terminal 
to His499 and reduces the overall dichroic ratio 
(helix tilt angle).  
The inactive mTpoR also exists in a 
monomer-dimer equilibrium (Fig. 9B). In the 
absence of the extracellular domain, the 
equilibrium shifts toward dimer. The interface 
mediating the inactive dimer in TM-JM peptides 
involves packing of Ala499 and Gly502. This 
interface is the same as that found in the 
engineered Put3 constructs (26). In the wild-type 
full-length receptor, ligand binding also drives a 
shift of the receptor dimer to an active orientation 
with Ser498 in the interface. Hydrogen bonding 
interactions involving Asn side chains stabilizes 
this orientation in the S498N mutant (Fig. 9B, 
right). 
 
DISCUSSION 
We show that several asparagine 
mutations in the TM domain of the mTpoR 
activate signaling, while only one asparagine 
substitution (S505N) does so for the hTpoR. Thus, 
human TpoR appears to be largely protected from 
oncogenic activation by Asn mutations. This 
major difference can be abolished if His499 in the 
hTpoR is substituted by leucine, the homologous 
residue in the mTpoR. We further show that 
His499 locally influences the structure and 
orientation of the TM helix and this change 
influences the ability of receptors with specific 
TM asparagine mutations to traffic to the cell 
surface.  
Receptor Dimerization in TpoR 
Signaling—Dimerization of the cytokine receptors 
is required for activation. The EpoR (24), PlR (42) 
and GHR (22,23) have been found to associate as 
pre-formed (inactive) dimers mediated by TM 
domain interactions. The implication is that there 
is a change in TM helix interfaces upon ligand 
binding and that this change is relayed to the 
intracellular domain to allow receptor activation.  
Our previous studies indicated that, upon 
ligand binding, or in the constitutively active 
S505N and W515K mutants, the monomer-dimer 
equilibrium shifts toward the active dimer (28). 
We extend these results here using the split 
luciferase assay to show that both the full-length 
hTpoR and mTpoR exist at a low level as 
preformed dimers, with the majority of chains 
detected as monomers. Interestingly, removal of 
the extracellular domain induces receptor 
dimerization in the mTpoR, but not the hTpoR.  
The model that emerges is one where 
ligand binding triggers a conformational change in 
the extracellular domain that allows receptor 
dimerization in an active conformation. Using 
structural approaches, we are able to mimic the 
dimerization behavior of the murine and human 
receptors when the extracellular domain is 
removed (i.e. the TM-JM peptides and the TM-IC 
constructs are largely monomeric for hTpoR and 
dimeric for mTpoR). This observation indicates 
that the extracellular domain blocks the ability of 
the TM helices to directly interact in the mTpoR. 
In the hTpoR, there is an additional mechanism 
that blocks helix association, namely the change in 
the helix conformation induced by His499. The 
H499L mutation induces constitutive dimerization 
of hTpoR in the absence of the extracellular 
domain in both the TM-IC constructs and the TM-
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JM peptides. In both the wild-type hTpoR receptor 
constructs and in the TM-JM peptides, the ability 
of the activating Asn mutations and eltrombopag 
(for hTpoR) to induce dimerization strongly 
suggests that helix association is a key element of 
the activation mechanism. 
The comparative studies on dimerization 
using the split luciferase assay between the full 
length WT TpoRs and the corresponding truncated 
TM-IC constructs show large differences in 
receptor dimerization. We have previously 
compared dimerization for hTpoR-WT and 
mEpoR-WT using the split luciferase assay and 
observed a two-fold difference in bioluminescence 
indicating that both the hTpoR and mEpoR 
receptors exist in a monomer-dimer equilibrium 
with mEpoR shifted more toward the receptor 
dimer (28). The subpopulation of pre-formed 
dimers may be the relevant form for rapid 
signaling by TpoR. While our studies reveal clear 
differences in dimerization in comparisons of (for 
e.g.) the full-length hTpoR and hTpoR TM-IC 
H499L, they open up the question as to how 
different cell types or membrane environments 
influence the monomer-dimer equilibrium. For 
example, there may be differences in the 
monomer-dimer equilibrium (and hence the level 
of pre-formed dimers) between TpoR-expressing 
cells, namely hematopoietic stem cells and 
megakaryocyte progenitors or there may be a shift 
in equilibrium if the membrane environment 
changes, such as incorporation of receptors into 
lipid rafts. The ability of the cell to modulate the 
monomer-dimer equilibrium would provide an 
additional control mechanism for receptor 
activation.  
TM Helix Orientation in TpoR Signaling—
The orientation of the TM and intracellular 
domains within dimers of single TM receptors is 
generally important for activation. In both the 
EpoR (32) and TpoR (26) we have shown using 
Put3 coiled-coil constructs that receptor activity is 
dependent on the orientation of the TM helix. For 
mTpoR, only one dimeric interface (cc-TpoR-II) is 
inactive. The cc-TpoR-II interface is lined with 
leucines, a AxxG motif, and ends with glutamine 
509 within the K/RWQFP motif, corresponding to 
Gln516 in the hTpoR. The AxxG sequence has 
similarities with the GxxxG sequences known to 
mediate TM dimerization (43,44). The close 
packing of the TM helices due to these small side 
chains places the mTpoR glutamine 509 into a 
position where it can mediate interhelical 
hydrogen bonding and stabilize dimerization. We 
ascribe this inactive interface to the same interface 
that mediates dimerization of the inactive TM-IC 
constructs of mTpoR. Moreover, we show with 
NMR (Fig. 8) that the TM-JM peptides (also 
lacking a large extracellular domain and hence 
similar to the TM-IC constructs) dimerize via the 
same interface as in the inactive cc-TpoR-II 
construct. 
In contrast, several interfaces in the Put3 
coiled-coil constructs have previously been shown 
to exhibit various levels of activity (26). cc-TpoR-
I induced high numbers of platelets, without other 
cytological features of myeloproliferation in bone 
marrow, and cc-TpoR-V induced a 
myeloproliferative phenotype with small red blood 
cells and variable levels of thrombocytosis (26). 
Thus, the active helix interfaces identified in the 
Put3 experiments are consistent with the Asn 
substitutions reported here, at least for the mTpoR. 
That is, the cc-TpoR-I and cc-TpoR-V interfaces 
involve the residues where asparagine mutations 
lead to the strongest activity (V494N, S498N, 
L501N and G502N). In cc-TpoR-V, the dimer 
interface is mediated by an SxxxG sequence, 
which again allows close helix packing. In our 
NMR studies, the S498N mutation induces a 
change in the conformation of the mTpoR peptide 
dimer and we lose the contacts between Ala499 
and Gly502 characteristic of the inactive dimer 
(Fig. 8). The low energy structure shown in Fig. 
9B corresponds to cc-TpoR-I, in which Asn498 
forms interhelical hydrogen bonds.  
Eltrombopag Drives Dimerization of 
hTpoR-WT—Eltrombopag is an FDA-approved 
drug used for the treatment of thrombocytopenia 
(low platelet numbers). Previous studies have 
found that eltrombopag can activate hTpoR, but 
not mTpoR (40). Eltrombopag and related small 
molecule agonists have been found to interact with 
His499 (41). We find that this transmembrane-
acting compound increases the dichroic ratio in 
FTIR measurements, induces helix in the Leu494-
Ala497 sequence in the TM domain and leads to 
receptor dimerization as assayed by deuterium 
NMR line shapes. The changes in dimerization 
induced by eltrombopag (Fig. 7B) are weaker than 
those observed for the H499L mutant (Fig. 7C). 
Nevertheless, eltrombopag appears to induce 
receptor activation in a similar manner as the 
S505N mutation, namely, both overcome the 
ability of His499 to inhibit TM dimerization.  
Multiple Levels of Regulation Involving 
the TM and JM Regions of TpoR—The wild-type 
hTpoR has several mechanisms for regulating 
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dimerization of the TM region of the receptor. 
These involve the extracellular domain, the TM 
His499 residue and the intracellular RWQFP 
insert. Removal of the extracellular domain or the 
H499L mutation alone does not induce 
dimerization. Both are required in the same 
construct. Ligand binding within the extracellular 
domain or mutations of Trp515 within the 
RWQFP insert can both overcome these 
mechanisms leading to an active receptor 
conformation. In the mTpoR, removal of the 
extracellular domain induces dimerization in an 
inactive conformation. Dual-luciferase 
measurements of receptor activation show that the 
TM-IC constructs of mTpoR are inactive. Thus, 
dimerization per se does not suffice for activation. 
Interestingly, the TM-IC constructs differ from the 
viral Mpl protein of the myeloproliferative 
leukemia virus by the presence of an extracellular 
domain of 109 amino acids comprised of 43 from 
the original murine sequence and 66 from the 
Friend murine leukemia virus. This suggests that 
the extracellular amino acids in the v-Mpl are able 
to stabilize the TM-IC portion of the receptor in an 
active orientation.  
Our results reveal that the TM helices in 
TpoR are not passive elements in ligand-induced 
dimerization. The TM helices have a stronger 
propensity to form dimers or higher order 
oligomers than to remain in a monomeric state. 
The extracellular, juxtamembrane and intracellular 
domains all contribute to modulating TM 
association. This observation may generally hold 
for ligand-induced activation of single TM 
receptors. For example, the TM helices in the 
ErbB family of receptor tyrosine kinases all have a 
strong propensity to dimerize (45) and removal of 
the extracellular domain can lead to active dimers 
(46,47) or can trigger intramembrane proteolysis 
(48,49). In these receptors, the juxtamembrane 
sequences play an influential role in dimerization 
and activation (50). Mutation of Val664 to Gln in 
the TM sequence of the ErbB2-Neu receptor can 
induce dimerization and constitutive receptor 
activation in a manner similar to the S505N 
mutation in hTpoR (51). 
The additional layer of activity control 
exerted by His499 in hTpoR may reflect the 
central role that this receptor plays in 
hematopoiesis. TpoR not only regulates 
megakaryocyte/platelet development, but also 
contributes to the survival of hematopoietic stem 
cells, which will give rise to all other blood cells. 
The acquisition of histidine at position 499 during 
evolution protects the hTpoR from the 
transforming effect of several Asn TM mutations 
that are activating in the mTpoR.  
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FIGURE LEGENDS 
 
FIGURE 1. Asparagine substitutions in the transmembrane domain of the human TpoR lead to activation 
of only one dimeric interface. A, TM sequences of hTpoR (upper) and mTpoR (middle) showing the 
position of His499 and the intracellular R/KWQFP motif. A consensus sequence (bottom) of 50 different 
mammalian TpoRs highlights (red) the positions with sequence identity of <90%. Four of these residues 
bracket Ser498 (murine) and Ser505 (human), which is highly conserved. B, Helical wheel diagrams of 
hTpoR (left) and mTpoR (right) showing the dimer interfaces that would be predicted for interacting 
helices in a left-handed coiled-coil geometry. C, Transcriptional activation of hTpoR after substitution of 
Gly503 to Leu510 with asparagine. γ2A cells were transiently transfected with JAK2 and the wild type 
TpoR or the different TpoR mutants and the activity of these receptors was assessed by measuring 
luciferase luminescence (in relative luciferase units, rlu) in the absence or in the presence of 50 ng/ml of 
Tpo as indicated. Only the S505N mutation triggers ligand-independent dimerization and signaling. D, 
BaF3 stably expressing the hTpoR variants were grown in the absence of cytokine or in the presence of 
different concentration of Tpo as indicated. Only TpoR S505N induced BaF3 autonomous growth. The 
presented values are averages of triplicates ± standard deviation (SD) for one representative experiment 
out of at least three. *P<0.01, **P<0.001, one way ANOVA.  
 
FIGURE 2. Asparagine substitutions in the transmembrane domain of the murine TpoR lead to 
activation of several dimeric interfaces. Leu492 to Gly502 were substituted with asparagine and these 
mutant receptors were assessed for their ability to signal in the absence of cytokine. A, γ2A cells were 
transiently transfected with the constructs and the transcriptional activation of STAT5 was measured by 
luciferase luminescence (in relative luciferase units, rlu). V494N, S498N, L500N, L501N and G502N 
triggered signaling in the absence of stimulation. B, BaF3 cells stably expressing the different constructs 
were grown and cell viability was measured in the absence of the presence of the different concentrations 
of Tpo ligand as indicated. V494N, S498N, L500N and G502N allow proliferation of BaF3 in the absence 
of cytokine. The values presented are averages of triplicates ± standard deviation (SD) for one 
representative experiment out of at least three. *P<0.01, **P<0.001, one way ANOVA between the wild-
type vs. each mutant in the absence of cytokine. 
 
FIGURE 3. Addition or removal of the TM histidine modifies the activity of the Asn mutants. A, 
Introduction of His instead of Leu at the homologous position in the murine receptor abrogated the 
activity of the G502N mutant as indicated on the dual luciferase assay performed in transiently 
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transfected γ2A cells. As control, eltrombopag (ETPG) was added and was able to activate the L492H 
receptor. B, Substitution of His499 by leucine restored the activity of the G509N mutant. Eltrombopag 
was no longer able to activate the receptor lacking His499. C, BaF3 cells stably expressing the TpoR 
variants were assessed for their ability to growth in the absence of cytokine (red) or in the presence of 
different concentrations of Tpo (gradient of blue, 1 ng/ml, 10 ng/ml, 50 ng/ml, 100 ng/ml) and 
eltrombopag (green, 0.7  µg/ml). Cells were all able to growth in the presence of IL3 (white). The human 
double mutant G509N/H499L and its murine homolog G502N were able to induce BaF3 autonomous 
growth in the absence of cytokine. Histograms are averages of triplicates ± standard deviation (SD) for 
one representative experiment out of at least three 
 
FIGURE 4. TpoR G509N is not expressed at the cell surface. A, Cell surface expression of HA-tagged 
TpoR was assessed by FACS using an anti HA.11 antibody. B, BaF3 cells were sorted for the same level 
of GFP. C, The total level of TpoR protein was assessed by Western blot with Np40 cells extracts using 
an anti-HA antibody. D, Endoglycosidase H (EndoH) and peptide-N-glycosidase F (PNGase) treatment of 
stable BaF3 cell lines. Sorted BaF3 stably expressing the TpoR asparagine variants have been treated with 
endoH (E) or PNGase treatment (P) or were not treated (-) and the total level of TpoR protein was 
assessed using an anti HA antibody by Western blot. All the receptors, except G509N mutant, were 
resistant to EndoH treatment revealing that the proteins are mature. The G509N mutant, which was fully 
degraded by EndoH is likely immature and does not process to the cell surface because of some 
misfolding that blocks it at the RER-Golgi transport system. All the receptors depend on N-glycosylation 
for processing as revealed by the PNGase treatment.  
 
FIGURE 5. Comparison reveals differences in the secondary structure and orientation of hTpoR and 
mTpoR TM peptides. A and B, Polarized IR spectra of hTpoR-WT and mTpoR-WT. C, 2D DARR NMR 
of mTpoR-WT using TM peptides isotopically labeled at 1-13C Leu487, 1-13C Val488, and 13Cβ Ala490. 
The cross peak (boxed) between the 13Cβ Ala490 and the 1-13C resonances of 1-13C-Leu487 and/or 1-13C 
Val488 is consistent with α-helical secondary structure in this region of the TM-JM peptide. D, Row 
through the 13Cβ Ala497 resonance of hTpoR showing the absence of a cross peak to either Leu494 or 
Val495, which is consistent with a kink or break in helical secondary structure in this region of the TM-
JM peptide.  (E) Row through the 13Cβ Ala490 resonance of mTpoR showing the strong cross peak to 
Leu487 and/or Val488. 
 
FIGURE 6. Comparison reveals differences in dimerization of the hTpoR and mTpoR TM peptides. 
Deuterium MAS NMR spectra of hTpoR-WT (A) and mTpoR-WT (B). The peptides contained deuterated 
leucine at positions 512 (hTpoR) or 505 (mTpoR). C, Dimerization of full-length hTpoR and mTpoR. 
Dimerization was detected using the split-luciferase assay in cell lysates. hGluc-tagged full-length or 
transmembrane/intracellular (TM-IC) forms of TpoR as well as mutant hTpoR(TM-IC) H499L were co-
expressed in BOSC cells and luciferase activity was measured after cell lysis. D, STAT5 transcriptional 
activity as measured by the split-luciferase assay. Histograms are mean ± standard error of the mean of 4 
independent experiments. *P<0.01, **P<0.001, one way ANOVA.  
 
FIGURE 7. Influence of His499 and eltrombopag on TM dimerization. Deuterium NMR spectra are 
shown of mTpoR-L492H (A), hTpoR-WT with eltrombopag (B) and hTpoR-H499L (C). The absence of 
side bands in the MAS spectra of mTpoR-L492H reflects rapid axial rotation of the peptide in the 
membrane bilayers. Dimerization induced in the hTpoR-WT peptide by eltrombopag and by the H499L 
mutation reduces axial diffusion rate and leads to increased intensity in the MAS sidebands.  
 
FIGURE 8. Interhelical NMR measurements of mTpoR peptides (Glu481 to Ser524). A, Row through the 
diagonal resonance of the Ala499 Cβ carbon reveals a cross peak with the Ala499 C=O resonance. In an 
inactive dimer the Ala499 Cβ to C=O distance is predicted to be ~5.4 Å. B, Row through the diagonal 
resonance of the Gly502 13Cα diagonal resonance reveals a cross peak with the Gly502 13C=O resonance, 
where the predicted interhelical distance is ~5.2 Å. In this sample, an intrahelical cross peak is also 
observed between the Gly502 Cα resonance and the Ala499 C=O resonance. C and D, DARR NMR 
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experiments were undertaken on mTpoR-S498N using the same labeling strategy as in (A,B). We do not 
observe Ala499-Ala499 or Gly502-Gly502 cross peaks in peptides containing this activating mutation.  
 
FIGURE 9. Models of the monomeric and dimeric TM domains of the hTpoR and mTpoR. A, Human 
TpoR. FTIR and NMR measurements on the TM-JM domain of hTpoR show that the wild-type peptide is 
primarily monomer (left) with a break in helical secondary structure in the region N-terminal to His499. 
In the S505N mutant of the hTpoR TM-JM domain (right), an increase in the dichroic ratio of the amide I 
vibration indicates that the TM helix is oriented closer to the bilayer normal, while the NMR 
measurements indicate that helix is induced in the region N-terminal to His499. In the full-length 
receptor, we propose that the monomer and inactive dimer (middle) are in equilibrium, and that either 
ligand binding or the S505N mutation shifts the equilibrium to the active dimer with either Ser505 (WT) 
or Asn505 (mutant) in the dimer interface. B, Murine TpoR. FTIR and NMR measurements on the TM-
JM domain of mTpoR show that the wild-type peptide is primarily dimer (middle) in which dimerization 
is mediated by close packing of Ala499 and Gly502. D, In the full-length receptor, we propose that the 
monomer (right) and inactive dimer are in equilibrium, and that either ligand binding or the S498N 
mutation shifts the equilibrium to the active dimer with either Ser498 (WT) or Asn498 (mutant) in the 
dimer interface. The dimer structures of hTpoR-S505N, mTpoR-WT and mTpoR-S505N were taken from 
computational searches using the program CHI (52,53) as previously described (26). These low energy 
structures correspond to the average of several structures in the searches that form clusters and best 
reproduce the experimental data presented here.  
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Table 1. Orientation, secondary structure and association of hTpoR-WT, mTpoR-WT and their 
mutants. 
 
Sequence Dichroic 
ratioa 
Helix tilt 
angle 
Leu494-Ala497 
Structure  
Leu494, Val495 
13C=O Shift (ppm) 
Association 
hTpoR-WT 2.7 ± 0.1 35° Extended 172.3, 172.3 Monomer 
S505N 3.4 ± 0.1 17° Helix 175.9, 175.9  Dimer 
G509N 2.5 ± 0.2 40° Extended 172.3, 172.3 Dimer 
H499L 3.2 ± 0.1 23° Helix 176.1, 176.1 Dimer 
hTpoR-WT + 
eltrombopag 
3.0 ± 0.1 28° Helix 175.3, 175.3 Dimer 
      
mTpoR-WT 3.3 ± 0.1 20° Helix 176.3, 176.3  Dimer 
S498N 3.3 ± 0.1 20° Helix 177.2, 177.2 Dimer 
G502N 3.2 ± 0.1 25° Helix 176.6, 176.6 Dimer 
L492H 2.6 ± 0.2 38° Extended 173.1, 173.1 Monomer 
 
a The error in the dichroic ratio corresponds to the standard deviation in 3 replicate runs.  
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 at SW
ETS SU
BSCRIPTIO
N
 SERV
IC on January 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
  Tpo Receptor Dimerization and Activation 
 25 
 
 
FIGURE 6 
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FIGURE 7 
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FIGURE 8 
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FIGURE 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 at SW
ETS SU
BSCRIPTIO
N
 SERV
IC on January 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Shwe Myat Marlar, Judith Staerk, Stefan N. Constantinescu and Steven O. Smith
Emilie Leroy, Jean-Philippe Defour, Takeshi Sato, Sharmila Dass, Vitalina Gryshkova,
Mutations of the Human Thrombopoietin Receptor
His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine
 published online December 1, 2015J. Biol. Chem. 
  
 10.1074/jbc.M115.696534Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/early/2015/12/01/jbc.M115.696534.full.html#ref-list-1
This article cites 0 references, 0 of which can be accessed free at
 at SW
ETS SU
BSCRIPTIO
N
 SERV
IC on January 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
